Tagged Articles

acute pancreatitis 180 articles

Long-term effects of new weight loss drug are yet to be determined

The diabetes drug turned weight loss drug is faring well in post-market studies when it comes to helping patients lose weight, but it could take months or years before serious side effects surface. The drug liraglutide was approved in January 2010 as a treatment for type 2 diabetes. Drug maker Novo Nordisk marketed the drug under the brand name Victoza, and hired Paula Deen, the now-former Food Network star, to be the drug’s spokesman. Paula even touted her weight loss since starting treatment with the drug. Paula wasn’t the only Victoza user who lost weight. The weight loss was noted in ... Read More

Experimental type 2 diabetes treatment fails in clinical trials

An experimental type 2 diabetes treatment made by Vitae Pharmaceuticals and Boehringer Ingelheim failed to significantly reduce blood sugar levels in patients when used with the first-line medication metformin, and analysts are wary that the medication will provide better results in trials testing it as a monotherapy. The drug was being tested as a treatment for obese patients with type 2 diabetes. The medication, currently known as VTP-34072, would have been the first drug in a class known as 11β-hydroxysteroid dehydrogenase type 1 inhibitor. It was discovered using Vitae’s Contour platform. VTP-34072 works by targeting an enzyme that produces a ... Read More

Novo Nordisk becomes top diabetes drug seller with Victoza

Danish drug company Novo Nordisk has become the top seller of diabetes medications thanks to its blockbuster type 2 diabetes treatment Victoza (liraglutide), which brought in a whopping $2 billion in sales, up 15 percent over last year. Novo Nordisk displaced Sanofi, which sells numerous insulin products including Lantus, insulin-delivery devices as well as the diabetes drugs Lyxumia (lixisenatide) and Amaryl/Amarel (glimepiride). Victoza was approved by the Food and Drug Administration (FDA) in 2010 and became one of the newer members of a new class of diabetes medications known as incretin mimetics. Other drugs in this class include Byetta/Bydureon (exenatide) ... Read More

Alarming number of pancreatitis, pancreatic cancer cases with diabetes drugs

Pancreatitis is a painful inflammation of the pancreas that can increase the likelihood of a patient developing pancreatic cancer, a health problem that type 2 diabetics are already at greater risk of developing. Interestingly, a study of drug adverse event reports reveals that common type 2 diabetes drugs have been associated with side effects that include acute pancreatitis and pancreatic cancer. Health informatics firm AdverseEvents scoured through post-marketing reports filed with the Food and Drug Administration (FDA) and found 1,900 cases of pancreatitis with AstraZeneca’s Byetta injection, 1,284 cases in patients taking Novo Nordisk’s Victoza, and 1,296 cases in patients ... Read More

Diabetes drugs may help reduce craving, but patients risk side effects

A class of type 2 diabetes drugs appear to change the brain’s response to food, leading to weight loss, and could also help people fight cravings for drugs, alcohol and nicotine as well, researchers suggest. The class of drugs, known as GLP-1 receptor agonists, or GLP-1 drugs, are known by the brand name diabetes treatments Bydureon, Byetta and Victoza. Since weight gain is already a contributing factor to the development of type 2 diabetes, the weight loss side effect offered by GLP-1 drugs is attractive. Late last year, Novo Nordisk received FDA approval for Saxenda, a high-dose version of its ... Read More

European regulators to review serious metabolic side effects with diabetes drugs

The European Medicines Agency (EMA) announced it will review the risk of a life threatening metabolic condition known as ketoacidosis from the use of certain type 2 diabetes drugs known as SGLT2 inhibitors. The review comes just after the U.S. Food and Drug Administration (FDA) ordered that warnings be placed on the labels of SGLT2 drugs advising patients and doctors of this risk. Ketoacidosis is a serious diabetes complication where the body produces excess blood acids, or ketones. It can lead to diabetic coma or death. It generally occurs when insulin levels are too low or during prolonged fasting. However, ... Read More

Diabetes drug Victoza being tested as treatment for fatty liver disease

Drug maker Novo Nordisk continues to look for new uses for its type 2 diabetes drug Victoza despite serious side effects including pancreatic cancer. The drug company is currently testing Victoza as a treatment for fatty liver disease, a condition for which treatments are limited. Victoza, which contains the active ingredient liraglutide, was shown to resolve fatty liver disease in more than a third of patients who participated in a small phase II study conducted by researchers from University of Birmingham in Britain. Fatty liver disease is the accumulation of fat on the liver that causes inflammation and scarring. It ... Read More

Weight loss from newer diabetes drugs may come at steep price

Newer classes of type 2 diabetes drugs can help patients lose weight, but that benefit may come at a high price. Being overweight is a risk factor for type 2 diabetes. Patients diagnosed with the chronic disease are generally advised to adopt a healthy diet and get regular exercise to help keep their blood sugar levels in check. Uncontrolled diabetes can increase the risk of serious health problems including heart disease, kidney disease, some cancers, blindness, neuropathy, and dementia. Losing weight through diet and exercise can help diabetics better manage and, in some cases, fend off the disease. However, reaching ... Read More

Study: Overweight diabetics live longer than normal weight diabetics

Type 2 diabetics who are overweight – but not obese – live longer than diabetics of normal weight, according to a new study published in the Annals of Internal Medicine. The so-called “obesity paradox,” which counters the conventional wisdom that maintaining a healthy weight will prolong life, has been seen with other health conditions. For example, studies have shown that while obesity increases the risk of developing cardiovascular disease, overweight patients with the condition outlive normal weight patients with heart disease. And, to confuse matters more, obesity increase the risk of developing type 2 diabetes. The new study on mortality ... Read More

Heart health concerns lead to more studies of newer type 2 diabetes drugs

Safety concerns with newer type 2 diabetes medications has prompted a new study into cardiovascular risks in patients who use the drugs. Earlier this month, a Food and Drug Administration (FDA) advisory panel recommended that two new diabetes drugs, Onglyza and Nesina, include new information about the risk of heart failure. The drugs are in a class of medications known as incretin mimetics, which includes the brand name diabetes drugs Victoza, Byetta and Januvia. Onglyza and Nesnia share a subclass known as DPP-4 inhibitors with Januvia, and this prompted researchers to take a closer look at cardiovascular risks with Januvia. ... Read More